Toon Van Gorp, MD, PhD, a MIRASOL trial investigator, emphasizes that the final analysis reinforces the efficacy of mirvetuximab soravtansine-gynx (Elahere; AbbVie) in patients with folate receptor ...

Two unique Hudson Institute research projects have been chosen among eight nationally to share in the largest-ever funding ...

Maintenance with niraparib and bevacizumab can be effective in patients with platinum-sensitive, recurrent ovarian cancer previously treated with a PARP inhibitor.

The discovery of the high-risk cells — a subset of progenitor cells that reside in fallopian tube supportive tissue, or stroma — may pave the way for better approaches to prevent and detect high-grade ...

Toon Van Gorp, MD, PhD, discussed findings from the MIRASOL trial and the potential of mirvetuximab to redefine treatment ...

Genmab A/S announced today updated data from cohort B1 of the Phase 1/2 RAINFOL-01 study of rinatabart sesutecan (Rina-S®), an investigational folate receptor-alpha (FR?)-targeted, TOPO1 antibody-drug ...

In a major advancement for ovarian cancer research, a team of scientists from the University of Pittsburgh has identified ...

AbbVie has reported analysis from a Phase III trial that assessed Elahere against chemotherapy for platinum-resistant ovarian ...

Scientists have uncovered a hidden driver of ovarian cancer—high-risk mesenchymal stem cells lurking in the fallopian tubes.

AbbVie has pointed to a very strong launch trajectory for Elahere, with sales rocketing to $480 million last year, almost ...

Researchers have discovered high-risk cells in fallopian tubes that could lead to high-grade serous ovarian cancer, paving ...

Researchers have discovered the likely origin of a deadly form of ovarian cancer, offering new hope for early detection and ...